LDK378, a novel ALK inhibitor approved for advanced-stage non-small cell lung cancer (NSCLC) with ALK gene rearrangement, exhibited promising anti-inflammatory activity in animal models of lethal sepsis. The gene discussed is ALK; the disease is non-small cell lung carcinoma.